Strategic partnerships DEINOVE collaborates with diverse stakeholders including academia, technology partners, industry players and non-profit drug discovery groups (e.g., Calibr). This presents opportunities to position co-development, licensing, or joint R&D programs around antimicrobial resistance solutions and bacterial biofactory platforms.

Clinical pipeline The lead antibiotic candidate is in Phase II for severe Clostridioides difficile infections, highlighting a near-term clinical proof point that can be leveraged to engage clinical trial networks, CROs, and hospital systems for companion diagnostics, biomarkers, and targeted antimicrobial strategies.

Platform capabilities DEINOVE houses a large proprietary collection of rare bacteria and a micro-factorial production approach, enabling both discovery and industrial production of complex antimicrobials. This supports sales opportunities in contract research, custom screening services, and scalable biomanufacturing partnerships.

Cosmetics-to-biotech bridge Past launches and collaborations on cosmetic actives (e.g., Luminity) indicate experience in bio-based ingredient development. There is potential to cross-sell antimicrobial or microbiome-related ingredients, sustainable biotech solutions, and contract R&D for cosmetic and personal care brands.

Funding and growth With modest revenue and early-stage funding, DEINOVE is actively pursuing partnerships to advance programs. Targeting investors, contract manufacturers, and strategic buyers in antimicrobial resistance and biotech manufacturing can unlock co-funding, scale-up, and distribution opportunities.